齐留通相关物质A | 171370-49-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 中文名称: 齐留通相关物质A
• 英文名称: [14C]-N-Dehydroxyzileuton
• 英文别名: N-Dehydroxyzileuton；A66193；[1-(1-Benzothiophen-2-yl)ethyl]urea；1-(1-benzothiophen-2-yl)ethylurea
• CAS: 171370-49-3
• 化学式: C₁₁H₁₂N₂OS
• mdl: MFCD00871300
• 分子量: 220.295
• InChiKey: CKVDCQYUEYONIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  83.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(氯甲酰)异氰酸酯 、 齐留通相关物质A 在 盐酸 作用下， 以 四氢呋喃 为溶剂， 生成 N-[1-(2-benzo[b]thienyl)ethyl]-N"-carbamoylurea 、
  参考文献：
  名称：

  N-[1-(2-Benzo[b]thienyl)ethyl]-N'-carbamoylurea and 1-[1-(2-Benzo[b]thienyl)ethyl][1,3,5]triazine-2,4,6-trione Methanol Solvate

  摘要：

  The title compounds, C12H13N3O2S and C13H11N3O3S.-CH4O, were prepared by treating the precursor urea, [1-(2-benzo [b]thienyl)ethyl] urea, with N-chlorocarbonyl isocyanate, The products were isolated by preparative thin-layer chromatography. Analytical samples were obtained by crystallization from methanol and the crystal structures of both compounds were determined.

  DOI：

  10.1107/s0108270195017215

文献信息

• Process for the Preparation of Zileuton
  申请人：Strides Shasun Limited

  公开号：US20160376251A1

  公开（公告）日：2016-12-29

  The invention discloses a process for the preparation of Zileuton of formula I by employing acetic acid-1-benzo[b]thiophen-2-yl-ethyl-ester of formula-III as an intermediate.

  本发明揭示了一种利用式III的乙酸-1-苯并[b]噻吩-2-基-乙酯作为中间体制备式I的Zileuton的方法。
• Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
  申请人：DermBiont, Inc.

  公开号：US11040077B2

  公开（公告）日：2021-06-22

  Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.

  本文公开了使用源自人类的 Lividum Janthinobacterium 的组合物和方法。组合物可改善皮肤健康。方法可包括在宿主或宿主区域（如皮肤或粘膜）上施用源于人的生发的Lividum Janthinobacterium，以最大限度地减少一种或多种微生物的存在，最大限度地提高治疗效果，和/或改善健康状况。减少病原微生物的方法可包括向表面施用一种组合物，该组合物包括来源于人类的Janthinobacterium lividum和一种可接受的载体。组合物和方法可包括益生元，以最大限度地提高生长和/或代谢物。组合物和方法可包括来源于人的猪蓝细菌代谢物，如violacein、prodigiosin、吲哚-3-甲醛、兰特益生菌和/或其他后益生菌。
• USE OF ARYL HYDROXYUREA COMPOUNDS FOR THE TREATMENT OF ATHEROSCLEROSIS
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0543855A1

  公开（公告）日：1993-06-02
• TOPICAL OLEAGINOUS COMPOSITIONS
  申请人：DR. REDDY'S LABORATORIES LTD.

  公开号：US20200054654A1

  公开（公告）日：2020-02-20

  A topical composition includes an oleaginous base and an active agent, which is useful for treating various skin disorders.
• COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES
  申请人：DermBiont, Inc.

  公开号：US20200345799A1

  公开（公告）日：2020-11-05

  Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum . Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.